Anas AlAhmed¹ and Hany Ezzat Khalil*^1,2‎

¹Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.

²Department of Pharmacognosy, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.

Corresponding Author E-mail: hanyzat@yahoo.com

DOI : https://dx.doi.org/10.13005/bpj/1680

Abstract

The main objective of current study was to investigate the in vitro and in vivo antidiabetic activity of Terfezia claveryi methanol extract. In vitro antidiabetic assays such as inhibition of α-amylase enzyme and non-enzymatic glycosylation of hemoglobin were carried out. The results of α- amylase inhibition assay revealed that the inhibitory activity (IC₅₀) of Terfezia claveryi methanol extract (‎38.7µg/ml) is stronger when compared with positive control (Acarbose IC₅₀ value of ‎45.3‎ µg/ml). The inhibition of glycosylation of hemoglobin of Terfezia claveryi methanol extract showed almost the same IC₅₀ (33.1µg/ml) when compared the positive control, alpha-tocopherol (‎35.4µg/ml‎). In vivo antidiabetic study revealed that Terfezia claveryi methanol extract ‎ possessed good activity at a dose of 200 mg/kg through reducing the fasting plasma glucose level (122.1‎±‎3.0 mg/dl) when compared with positive control (Glibenclamide of ‎79.4±1.4‎ mg/dl) (p < 0.001). The results from this study indicated that Terfezia claveryi methanol extract exhibited considerable in vitro and in vivo antidiabetic activities. These possible activities could be useful to consider Terfezia claveryi ‎ as therapeutic antidiabetic candidate.

Keywords

Antidiabetic; α-amylase; Hemoglobin; Streptozotocin; Terfezia

Download this article as: 

Copy the following to cite this article: AlAhmed A, Khalil H. E. Antidiabetic‎ Activity of Terfezia Claveryi; an In Vitro and In Vivo Study. Biomed Pharmacol J 2019;12(2).

Copy the following to cite this URL: AlAhmed A, Khalil H. E. Antidiabetic‎ Activity of Terfezia Claveryi; an In Vitro and In Vivo Study. Biomed Pharmacol J 2019;12(2). Available from: https://bit.ly/2ZOyadd

Introduction

Diabetes is considered one of the world’s largest endocrine disease, that characterized by an increased blood glucose level (hyperglycemia). Clinically, Diabetes is classified as type-1(T1DM) characterized by insulin deficiency and type-2 (T2DM) characterized by insulin inefficiency. Uncontrolled diabetes could lead to severe complications to the cardiovascular system ¹. Natural products have aided humans since long ages. They are considered as sources of important active ingredients. In comparison with synthetic drugs, synthetic one may cause many drawbacks such as vomiting, diarrhea, fluid retention, allergic reaction². Recently, the International Diabetes Federation (IDF) 7th edition of the Diabetes Atlas specified that 415 million people worldwide is diabetics³. T2DM represents about 90-95% of all cases of diabetes ⁴. T2DM is considered one of the main international health concerns. T2DM affects around 422 million people all over the world⁵. Prediabetes and diabetes prevalence and complications are growing in a bothersome way. By year of 2035, it is anticipated that about 592 million people will suffer from DM⁶. The treatment of T2DM is currently achieved through the usage of conventional drugs that are effective in treatment of diabetes but to some extents still accompanied by some undesirable effects⁷. The management of diabetes is considered a global problem and the search for a definite therapy is still ongoing.  Truffle is a fungus, which grows wildly in desert regions depending on water rainfall⁸. In addition, many researches stated that truffle can be used in many purposes such as source of energy, activation of sex hormones, and as antibiotics against gram positive bacteria including Bacillus subtilis and Staphylococcus aureus ^9-11. Terfezia boudieri ethanol extract showed anti-hyperglycemic effect ‎ on streptozotocin (STZ) induced-diabetic rats ⁸.  Currently, there are no research studies were conducted to investigate the in vitro and in vivo antidiabetic potential of Terfezia claveryi ‎. The previously mentioned data provoked us to assess ‎ the α-amylase inhibitory activity and effect on inhibition of glycosylation of hemoglobin as well as in vivo studies in streptozotocin-induced diabetic rats to evaluate and confirm its potential hypoglycemic effect.

Material and Methods

Plant Material

Terfezia claveryi (T. claveryi) was purchased from a local folk market in spring season, Al-Hasa, eastern region of Saudi Arabia. The fungus was subjected to air-drying according to the standard protocols. T. claveryi ‎ was kindly identified by Dr. Mamdouh Shokry, director of El-Zohria botanical garden, Giza, Egypt. A voucher specimen was kept in Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Hasa, Saudi Arabia (03-17-Apr-TC).

Extraction and Fractionation of Different Plant Organs Extracts

The air dried powdered material (500.0 g) was exhaustively extracted three times at room temperature (for 5 days) using 3l of 70 % MeOH/H₂O applying cold maceration technique at room temperature to protect the potential active ingredients from being decreased or destroyed. The solvent mixture was removed through distillation under vacuum using Rota vapor and dried extracts were directly freeze-dried to give the total methanol extract weighting 60.2 g that were kept in -20^oC for the next steps ¹².

Animals

Male Wistar albino rats having a weight of 150 – 210 g were kept in quarantine for 2 weeks under standard husbandry conditions (27^o, Relative humidity 65±10 %) for 12 h in dark and light cycle, respectively, and were given standard food and water ad libitum ¹³. All of the experiments were done in this study according to the Animal Ethics Committee of King Faisal University.

Chemicals

Acarbose, glibenclamide, streptozotocin, metformin, gentamycin, α-amylase from porcine pancreas, hemoglobin porcine and alpha-tocopherol were purchased from Sigma Aldrich (ST. Louis. Mo, USA). Solvents used for extraction and assays were all of analytical grade.

In Vitro Anti-Diabetic Models

α-Amylase Inhibitory Activity

The assay mixture was prepared to contain 0.02M sodium phosphate buffer (200 μl), α-amylase enzyme ‎(20 μl, 2 unit/ml) ‎ together with different plant extracts in the range of concentrations 20-100 μg/ml. Then, it was incubated for 10 min at room temperature followed by the addition of 200 μl of 1 % starch suspension to all the tubes containing reaction mixture. The reaction was later terminated by the addition of 400 μl of 3, 5 di-nitro salicylic acid (DNSA) color reagent. Then the tubes were kept in boiling water bath for 5 minutes, and later were kept till being cooled at room temperature and diluted with 15 ml of distilled water. The absorbance of each reaction mixture was measured at 540 nm. Control mixture reactions were also prepared accordingly without addition of extracts of plant under investigation and were compared with the test samples containing concentration of different plant extracts (20-100 μg/ml) freshly prepared in DMSO. The results were indicated as % of inhibition of activity using the following formula:

where; Abs (control) is the absorbance of the control reaction (containing all reagents except the test sample) and Abs (sample) is the absorbance of different plant extracts^14,15. The IC₅₀ values (inhibitory concentration which will produce 50 % inhibition of the enzyme activity) of the plant extracts were determined. Acarbose which is a well-known and safe anti-diabetic drug used to treat T2DM, was applied as a positive control in the concentrations ranged from 20 to100 ‎µg/ml‎¹⁶. Experiments were achieved in triplicates

Non-Enzymatic Glycosylation of Hemoglobin Assay

Solutions of glucose (2 %), hemoglobin (0.06 %) and gentamycin (0.02 %), were freshly prepared in phosphate buffer (0.01 M, pH 7.4). One ml of each of above mentioned solution was mixed. One ml of each concentration of different plant extracts (20-100μg/ml) was added to the prepared mixture. Then, the test tubes containing reaction mixture were incubated in dark place at room temperature for three days. After, the degree of glycosylation of hemoglobin was obtained colorimetrically at 520 nm where the percentage of inhibition was calculated applying this formula:

where; Abs (control) is the absorbance of the control reaction (containing all reagents except the test sample) and Abs (sample) is the absorbance of different plant extracts. The IC₅₀ values (inhibitory concentration which will produce 50% inhibition of the enzyme activity) of the plant extracts were determined. Alpha-Tocopherol was used as a standard drug^14-16. Experiments were carried out in triplicates

In Vivo Anti-Diabetic Model

Acute Toxicity Testing

Acute toxicity testing was performed for T. claveryi total methanol extract, were studied where the rats took ascending oral doses up to 2000 mg/kg of each extract, and signs and symptoms of toxicity were observed for the next 48 h ¹⁷.

Induction of Diabetes

Diabetes was induced by intraperitoneal (i.p.) injection of streptozotocin (STZ) dissolved in 0.1 M cold citrate buffer (pH=4.4) at a dose of 60 mg/kg body weight. On the third day after STZ injection, fasted blood glucose levels were measured by hand-held glucose monitoring (BAYER Contour). Only rats with serum glucose levels of 190-200 mg/dl were selected and considered diabetic animals ¹⁸.

Experimental Design

The animals were segregated into five groups of five rats each. Group I served as normal control rats, administered drinking water and 0.1 M cold citrate buffer (pH=4.4) daily for 12 d; Group II had diabetic control rats, administered drinking water daily for 12 days; Group III diabetic rats were administered T. claveryi total methanol extract (200 mg/ kg) for 12 d; and Group IV diabetic rats were administered standard drug glibenclamide (0.25 mg/kg) for 12 d. The fasting glucose levels were determined on days 1, 5, and 12 of extracts administration ^{3, 17, 18}.

Statistical Analysis

Values were expressed as mean±SE‎ (Standard Error) ‎. To analyze the differences between groups, statistical analysis was performed by one-way ANOVA followed by post-hocTukey using a computer soft program SPSS v.20. Significance was considered at a p value <0.05.

Results

α-Amylase Inhibitory Activity

The in vitro α-amylase‎ inhibitory measurements demonstrated that T. clavery total methanol extract has potential of α- amylase inhibitory possessions. α-amylase inhibitory activities were compared based on the calculated IC₅₀ values (Table 1). The observed α-amylase inhibitory activity of T. claveryi total methanol extract was (‎38.7 µg/ml). Acarbose was used as the positive standard. It showed IC₅₀ value of ‎45.3‎µg/ml‎ under similar conditions.

Table 1: α- amylase inhibitory effect of T. claveryi total methanol extract.‎

	percentage of inhibition
conc. µg/ml	T. claveryi  methanol‎ extract	standard (Acarbose)‎
20	‎17.1±‎0.9	‎32.2±‎1.1
40	‎28.0±1.1	‎43.8±‎1.3
60	‎54.2±‎‎ 1.3	‎64.9±‎2.3
80	‎59.5±‎1.1	‎75.5±‎1.4
100	‎68.4±1.7	‎81.1±1.3
IC50 µg/ml	38.7	45.3

 

Values were expressed as mean ± SE (Standard Error) n=3 independent experiments.

Non-Enzymatic Glycosylation of Hemoglobin Assay

The inhibitory activities of T. claveryi total methanol extracts were recorded (Table 2). T. claveryi total methanol extract showed almost the same value of IC₅₀ (33.1 µg/ml) to the positive control, alpha-tocopherol (‎35.4 ‎µg/ml).

Table 2: Non-enzymatic glycosylation of hemoglobin effect by T. claveryi total methanol extract.

	percentage of inhibition
conc. µg/ml	leaves methanol extract	standard (alpha-Tocopherol)‎
20	24.4±1.2	38.8±0.5
40	28.5±0.3	49.3±0.6
60	34.6±1.3	71.6±0.6
80	44.2±1.5	81.0±1.0
100	50.5±0.5	82.7±1.6
IC50 µg/ml	33.1	35.4

 

Values were expressed as mean ± SE (Standard Error, n=3 independent experiments.

Acute Toxicity Study

No toxicity or death was observed in the experimental rats. Hence 200 mg/kg (1/10 of the 2000 mg/kg) was selected as a maximum safety dose.

In vivo antidiabetic activity

The effect of T. claveryi total methanol extract ‎ on fasting blood glucose levels of diabetic rats was presented in table 3. In diabetic rats, as shown in table 3‎, T. claveryi total methanol extract and glibenclamide had a significant time dependent hypoglycemic activity, compared with the diabetic control group at each time point (p<0.001).

Table 3: Results of the in vivo study on STZ-induced diabetic rats by T. claveryi total methanol extract.

Groups	Fasting plasma glucose concentration (mg/dl)
	Day 1	Day5	Day12
I- Normal control ‎	‎79.9±1.2 ‎ ‎‎	80.9±0.8	‎81.6±1.1
II- Diabetic control‎ (streptozotocin)‎ ‎(55 mg/kg)  ‎	196.8±2.4	‎198.18±1.6	200.3±2.5
III- Diabetic + leaves methanol extract ‎(200 mg/kg)	197.9±1.9	138.6±1.6*	122.1±3.0*
IV- Diabetic + standard glibenclamide (0.25 mg/kg)	196.5±1.5	91.38±1.1*	79.4±1.4*

 

Values were expressed as mean ± SE (Standard Error), (n=6), *significantly different from diabetic control (p<0.001).

Discussion

α-Amylase enzyme is one of the enzymes responsible for the hydrolysis of α-oriented bond polysaccharides and oligosaccharides such as starch, glycogen and other macromolecules of α-bond linked monosaccharides to disaccharides and finally to glucose^19-22. T. claveryi total methanol extract ‎ showed promising result in α-amylase inhibition assay, suggesting that T. claveryi might be effective in slowing down hydrolysis of starch to minimized glucose availability.

In vitro non-enzymatic glycosylation of hemoglobin method is one of important assays to judge the control of diabetes. The hemoglobin present in RBCs has an affinity to bind to glucose. The greater the glucose level in blood, more amount of glucose-bound (called glycosylated) hemoglobin will be formed. Such glucose hemoglobin association is to some extent stable and stays for1-2 months (the life-span of red blood corpuscles) ^{22, 23}. Consequently presence of higher concentration of glycosylated hemoglobin is a sure guide to the higher concentration of glucose in the blood. Normally, the percentage of glycated hemoglobin should not be exceeding 12%. The current study demonstrated good activity of T. claveryi total methanol (almost the same that of positive control, alpha-tocopherol) in preventing such binding of glucose to surface proteins of erythrocytes.

The fundamental mechanism underlying elevated blood sugar in diabetes mellitus involves over-production and decreased utilization of glucose by the tissues. In the current study, the difference observed between the initial and final fasting plasma glucose levels of different groups under investigation, revealed a significant elevation in blood glucose in the diabetic control group as compared to normal animals, at the end of the twelve-day experimental period. When T. claveryi total methanol was administered to diabetic rats, a decrease in plasma glucose level was observed after 12 days. T. claveryi total methanol reduced plasma glucose (Table 3). During the study it was found that T. claveryi total methanol significantly controlled the blood glucose level in Streptozotocin-induced diabetic rats as compared to the diabetic control group (Table 3).

Conclusion

The above conducted in vitro examinations depict a substantial α-amylase inhibitory and percentage of inhibition glycosylation of hemoglobin of T. claveryi total methanol. Which was further confirmed by in vivo studies that showed T. claveryi total methanol significantly controlled the blood glucose level diabetic rats. It could be therefore conclude from this study that T. claveryi can serve as a therapeutic agent and can be used as a potential source of new antidiabetic product.

Conflict of Interest

There is no conflict of interest.

References

1. H E Khalil, A G A Alharbi and I M Ibrahim. In vitro antidiabetic assessment of Ocimum forskolei L growing in Saudi Arabia. Journal of Pharmacognosy and Phytochemistry, 8: 355-357(2019).
2. S S Nair, V Kavrekar and A Mishra. Evaluation of in vitro antidiabetic activity of selected plant extracts. Int J Pharm Pharm Sci Invent, 2:12-19(2013).
3. S M Ezzat, A Abdel Motaal and S A El Awdan. In vitro and in vivo antidiabetic potential of ‎extracts and a furostanol saponin from Balanites aegyptiaca. Pharm Biol ‎, 55:1931-6(2017).‎
4. B T Zhao, D D Le, P H Nguyen, M Y Ali, J S Choi and B S. PTP1B, α-glucosidase, and DPP-IV inhibitory effects for chromene derivatives from the leaves of Smilax china Chemico-Biological Interactions, 253:27-37(2016).
5. WHO, 2016. World Health Day 2016: WHO Calls for Global Action to Halt Rise in and Improve Care for People with Diabetes. Available at: http://www.who.int/mediacentre/news/releases/2016/world-health-day/en/.
6. S H Seong, A Roy, H A Jung, H J Jung and J S Choi. Protein tyrosine phosphatase 1B and α-glucosidase inhibitory activities of Pueraria lobata root and its constituents. J Ethnopharmacol, 194:706-16(2016).
7. K S Jyothi, P Hemalatha and S Challa. Evaluation of α-amylase inhibitory potential of ‎three medicinally important traditional wild food plants of India. Int J Green ‎Pharm, 5:95-9(2011).‎
8. K A Shakshak, A M Afan, A A Auzi and A M. Hamrouni. The Hypoglycemic Effect of Libyan Truffle “Terfezia Boudieri” in Experimentally Induced Diabetic Rats. Tripolitana Medical Journal, 3:1-4(2014).
9. Q A Mandeed and A A Al-Laith. Ethnomycological aspects of the desert truffle among native Bahraini and non- Bahraini peoples of the Kingdom of Bahrain. Journal of Ethnopharmacology, 11:118-129‎(2007)‎.
10. G Hussain and I M Al-Ruqaie. Occurrence, chemical composition, and nutritional value of Truffles: an overview. Pakistan Journal of Biological Sciences, 2:510-514(1999).
11. S Janakata and M Nassar. Hepatoprotective activity of desert truffle (Terfezia claveryi) in comparison with the effect of Nigella sativa in the rat. Pakistan Journal of Nutrition, 9:52-58(1999).
12. H E Khalil and A Al Ahmed. Phytochemical Analysis and Free Radical Scavenging Activity of Carthamus oxyacantha growing in Saudi Arabia: A Comparative Study. Int J Pharm Sci Rev Res, 45:51-55(2017).
13. ‎M Sobeh, M F Mahmoud, M A Abdelfattah, H A El-Beshbishy, A M El-Shazly and M Wink. ‎Hepatoprotective and hypoglycemic effects of a tannin rich extract from Ximenia americana ‎ caffra root. Phytomedicine, 33:36-42‎(2017).
14. A A Muchandi, A S Jadhav, S B Patil, S A Patil and N B Jadhav. Antioxidant and In Vitro ‎Antidiabetic Activity of Methanol Extract of Piper cubebaA review. Int J Res ‎Ayu Pharm, 8:81-87(2017).‎
15. ‎N Santhiya, S Priyanga, S Hemmalakshmi and K Devaki. Phytochemical analysis, ‎Anti-inflammatory activity, in vitro antidiabetic activity and GC-MS profile of ‎Erythrina variegata bark. J Appl Pharm Sci, 6:147-55(2016).‎
16. P Phillips, J Karrasch , R Scott, D Wilson and R Moses. Acarbose improves glycemic control ‎in overweight type 2 diabetic patients insufficiently treated with metformin. ‎Diabetes Care, 26:269-73(2003).‎
17. U Sharma, R K Sahu, A Roy and D K Golwala. In vivo antidiabetic and antioxidant ‎potential of ‎Stephania hernandifolia in streptozotocin-induced-diabetic rats. J Young ‎Pharm, 2:255-‎‎60 (2010).‎
18. ‎ L S Wan, C P Chen, Z Q Xiao, Y L Wang, Q X Min and Y Yue. In vitro and in vivo anti-diabetic ‎activity of Swertia kouitchensis J Ethnopharmacol, 147:622-30‎(2013).
19. G Suganya, K P Sampath, B Dheeba and R Sivakumar. In vitro antidiabetic, antioxidant and ‎anti-inflammatory activity of Clitoria ternatea. L. Int J Pharm Pharm Sci, 2017; ‎‎6:342-7(2017).‎
20. M I IKotowaroo, M F Mahomoodally , A Gurib‐Fakim  and A H Subratty . Screening of ‎traditional antidiabetic medicinal plants of Mauritius for possible α‐amylase ‎inhibitory effects in vitro. Phytother Res, 20:228-31(2006).‎
21. N Abirami, B Natarajan and E Sagadevan. Phytochemical investigation and in vitro ‎evaluation of hypoglycemic potential of Grewia hirsuta. Int J Pharm Bio Sci, ‎‎5:76-83(2014).‎
22. S Radhika, K R Senthil, S Sindhu, E Sagadevan and P Arumugam. Phytochemical ‎investigation and evaluation of antihyperglycemic potential of Premna ‎corymbosa. Int J Pharm Pharm Sci, 5:352-356(2013).‎
23. G U Daksha, K S Chandrashekar and G I Pai. In vitro antidiabetic ‎activity ‎of ‎pentacyclic tritrpenoids and fatty acid esters from Bauhinia purpurea. ‎Int ‎J ‎Pharmacol Pharm Technol,2:25-8(2013).‎